Market news · Nov 13, 12:02 PM ET

FTC sues to block Covetrus's $3.5 billion purchase of MWI from Cencora

The Federal Trade Commission sued on November 13, 2026 to stop Covetrus from buying rival MWI Veterinary Supply from Cencora for $3.5 billion, arguing the deal would raise prices for veterinary clinics and pet owners. Cencora and the private-equity owners of Covetrus are the main companies exposed, and the outcome could affect how US antitrust regulators treat consolidation in animal health distribution.

What the regulator is alleging

The Federal Trade Commission sued to block Covetrus Inc. and its owners from acquiring MWI Veterinary Supply from Cencora for $3.5 billion. The agency says the two businesses are the largest suppliers in the markets for veterinary clinic distribution and for distribution to large corporate accounts, and that combining them would concentrate those markets.

According to the FTC's complaint, the merged company would push up costs for clinics, weaken service and raise prices for pet owners. The complaint says Covetrus and MWI are head-to-head rivals that already compete hard on price, including through rebates and a price war that the agency describes as years in the making.

Covetrus and MWI sell pharmaceuticals, vaccines, basic supplies such as gloves and syringes, surgical products and related services. Their customers range from single-doctor practices to chains with hundreds of clinics across the country.

Who is involved

Covetrus is owned by private equity firms Clayton, Dubilier & Rice and TPG. The US Federal Trade Commission filed a lawsuit to block CD&R- and TPG-owned (TPG) Covetrus from purchasing MWI Veterinary Supply, which is owned by Cencora (COR). Cencora's own description of the deal was not available in the material used for this story.

A coalition of state attorneys general joined the federal action. Nebraska's attorney general said it joined the Federal Trade Commission alongside Arizona, Arkansas, California, Colorado, Maine, Michigan, Minnesota, New York, North Carolina, Ohio, Oregon, and Texas in filing the case.

The deal was first announced in February, according to a Bloomberg report cited by PYMNTS. That report said Cencora would retain a minority, non-controlling interest in the combined business after the transaction closes.

Why it matters for US investors

For Cencora, the suit puts a $3.5 billion divestiture in doubt. Cencora is the listed company on the sell side, and its shares would be affected by any delay or failure of the sale. The companies did not say in the material reviewed how they would proceed.

For TPG, the outcome bears on a portfolio company in animal health distribution, where it is a co-owner of Covetrus alongside CD&R. Neither firm's response to the lawsuit was available at the time of writing.

The case also matters beyond the two companies. Regulators are scrutinizing consolidation in veterinary distribution, and a state attorney general said the combined business would control over 50% of the veterinary distribution market nationally. Bloomberg, as cited by PYMNTS, reported that the FTC had been asking customers and rivals for information, including about veterinary practice-management software, which clinics use to manage patient records, prescriptions and billing.

What comes next

The complaint was filed in the U.S. District Court for the Southern District of New York, and the FTC's vote to authorize the case was 2-0. The FTC's complaint seeks a permanent injunction, so the court would decide whether the deal can proceed. No timeline for a ruling was given.

  • Covetrus, MWI and Cencora had not publicly responded in the material reviewed.
  • The case is a federal court action, not a final decision.
  • The complaint centers on clinic distribution and large corporate accounts, not on the wider animal health market.
Federal Trade CommissionCencoraCovetrusMWI Veterinary SupplyCD&RTPG

Sources

Written with AI assistance on Nov 13, 12:02 PM ET from the reports listed under Sources, and reviewed by our editor after publication. Before it was published, every figure was checked against those reports, and passages with figures that could not be found there were left out. It can still contain mistakes: read the sources before acting on anything. How we review. Not investment advice.